galantamine hydrobromide, 1953-04-4

Articles:

PubMed:	Gypsogenin Derivatives: An Unexpected Class of Inhibitors of Cholinesterases.
PubMed:	Determination of galantamine hydrobromide in bulk drug and pharmaceutical dosage form by spectrofluorimetry.
PubMed:	Benzophenones from Hypericum elegans with antioxidant and acetylcholinesterase inhibitory potential.
PubMed:	Synthesis of imperatorin analogs and their evaluation as acetylcholinesterase and butyrylcholinesterase inhibitors.
PubMed:	Quantification of galantamine in human plasma by validated liquid chromatography-tandem mass spectrometry using glimepride as an internal standard: application to bioavailability studies in 32 healthy Korean subjects.
PubMed:	Controlled release reservoir mini tablets approach for controlling the drug release of Galantamine Hydrobromide.
PubMed:	Development and in vivo evaluation of novel monolithic controlled release compositions of galantamine hydrobromide as against reservoir technology.
PubMed:	Stability-indicating study of the anti-Alzheimer's drug galantamine hydrobromide.
PubMed:	The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome.
PubMed:	Galantamine is a novel post-exposure therapeutic against lethal VX challenge.
PubMed:	Bullous pemphigoid precipitated by galantamine hydrobromide.
PubMed:	Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
PubMed:	A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease.
PubMed:	[Criminal clozapine intoxications].
PubMed:	Pharmacokinetics and bioequivalence studies of galantamine hydrobromide dispersible tablet in healthy male Chinese volunteers.
PubMed:	Cholinesterase inhibitors in the treatment of dementia.
PubMed:	Capillary electrophoresis-mass spectrometry in impurity profiling of pharmaceutical products.
PubMed:	A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.
PubMed:	Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial.
PubMed:	The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease.
PubMed:	Pharmacokinetics and tissue distribution of galantamine and galantamine-related radioactivity after single intravenous and oral administration in the rat.
PubMed:	The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
PubMed:	Antioxidant properties of galantamine hydrobromide.
PubMed:	Galantamine hydrobromide: an agent for Alzheimer's disease.
PubMed:	Gateways to clinical trials.
PubMed:	Gateways to clinical trials.
PubMed:	Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
PubMed:	Gateways to Clinical Trials. June 2002.
PubMed:	Galantamine hydrobromide.